Propofol Effects on Mitral Valve Annular Velocity

Konkuk University Medical Center40 enrolled

Overview

The purpose of this study is primarily to determine the effects of propofol at different concentration on the mitral valve annulus by using Tissue Doppler Imaging

The purpose of this study is to evaluate the effects of different concentration of propofol on patients who are undergoing cardiac surgery. The patients will receive infusion remifentanil 0.5mcg/kg/min with different target-site propofol concentration namely 1.0ng/ml, 2.0ng/ml and 3.0ng/ml. Tissue Doppler Imaging by transesophageal echocardiography will be done to assess the changes in cardiac function.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Valvular Heart Disease Coronary Artery Disease

Interventions

Propofol 1.0mcgDRUG

Propofol dosage titration to achieve effect site concnetration at 1.0 mcg/ml using target controlled infusion.

Propofol 2.0mcgDRUG

Propofol dosage titration to achieve effect site concnetration at 2.0 mcg/ml using target controlled infusion.

Propofol 3.0mcgDRUG

Propofol dosage titration to achieve effect site concnetration at 3.0 mcg/ml using target controlled infusion

Eligibility

Sex: ALLMin age: 20 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: patients undergoing cardiac surgery Exclusion Criteria: low ejection fraction \< 50% on transthoracic echocardiography atrial fibrillation pacemaker pericardial and infiltrative myocardial disease mitral annular calcification, surgical rings, prosthetic mitral valve lateral left ventricular wall motion abnormality oesophageal abnormality history of extensive radiation to the mediastinum upper gastrointestinal bleeding

Locations (1)

Konkuk University Medical Center

Seoul, Seoul, South Korea

Outcomes

Primary Outcomes

Change of systolic mitral valve annular velocity (S')

To examine the effect of Propofol at different effect-site concentration ( 1.0 ng/ml, 2.0 ng/ml and 3.0 ng/ml) on S' (systolic mitral valve annular velocity) during remifentanil-based anesthesia.